Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. Granholm A, Kjaer MN, Munch MW, Myatra SN, et al. Intensive Care Med 2022 Mar 31. pii: 10.1007/s00134-022-06677.

Read + Share

Amedeo Smart

Independent Medical Education

Granholm A, Kjaer MN, Munch MW, Myatra SN, et al. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. Intensive Care Med 2022 Mar 31. pii: 10.1007/s00134-022-06677.
PMID: 35359168